Compare Inovio Pharmaceuticals Inc (INO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Novartis AG — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Novartis AG trades at $154.44 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3251.4× Inovio Pharmaceuticals Inc's market cap, and Novartis AG pays a 3.17% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NVS | |
|---|---|---|
Market Cap | $89.27M | $290.25B |
Sector | Health | Health |
52-Week High | $2.87 | $168.62 |
52-Week Low | $1.05 | $113.50 |
Enterprise Value | $60.28M | $330.27B |
Dividend Yield | — | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $149.85, down 2.54% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong 2025 results with $56.67B revenue and $13.98B net income, though recent quarterly EPS results have been mixed. Key developments include FDA approval for Fabhalta and the $1.5B acquisition of Myricx Bio to expand its oncology pipeline.
Outlook remains cautiously optimistic with 68% analyst hold ratings reflecting valuation concerns at 22.03 P/E. Near-term catalysts include Q2 2026 earnings and drug trial readouts, while risks involve pipeline execution and premium valuation pressure. The stock offers stability with robust profitability but faces growth execution tests ahead.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
